
About HaemO2
HaemO2 was a Healthcare company based in United States founded in 2011. It develops engineered hemoglobin for creating advanced blood substitute solutions. It operates on a B2B model. HaemO2 has raised $184.63 thousand across 1 funding round from investors including IceniFund. The company is recorded as dissolved. Its focus areas include Biotechnology, Medical Devices and Blood Substitutes. Its legal entity in India is Emotion Squared Technologies Private Limited (U72900TN2011PTC079107). Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
HaemO2 operates with a B2B model, focusing on providing healthcare solutions, advancing biotech innovations, developing medical devices, and blood substitutes. Develops engineered hemoglobin for creating advanced blood substitute solutions. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
- Headquarters University, United States
- SectorsHealthcare
- Website haemo2.com
- Social X
- Legal Name Emotion Squared Technologies Private Limited
- Date of Incorporation 08 Feb, 2011
- Jurisdiction Chennai, Tamil Nadu, India
- Total Equity Funding$184.63K (USD)
in 1 rounds
- Latest Funding Round$184.63K (USD), Seed
Jan 2012
- Investors
Associated legal entities of HaemO2
HaemO2 operates through Emotion Squared Technologies Private Limited (strike off). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Emotion Squared Technologies Private Limited CIN U72900TN2011PTC079107 | Strike Off | 08 Feb 2011 | Chennai, Tamil Nadu | 2 | View details |
Funding Insights of HaemO2
HaemO2 has successfully raised a total of $184.63K through 1 strategic funding round. The most recent funding activity was a Seed round of $184.63 thousand completed in January 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $184,626
- Total Rounds 1
- Last Round Seed β $184,626
- First Round $184,626
(Jan 2012)
- Investors Count 1
All 2 funding rounds of HaemO2 with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2013 | $145,945 | Grant | β | β | |
| Jan 2012 | $184,626 | Seed | β | β |
1 investors in total: 1 institutional.
Investors in HaemO2
HaemO2 has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include IceniFund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Image compression tools are provided for optimizing file sizes. | icenifund.com |
Investor details for HaemO2
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Emotion Squared Technologies Private Limited (HaemO2)
Emotion Squared Technologies Private Limited is the primary company behind HaemO2. The board of Emotion Squared Technologies Private Limited currently have 2 directors; the longest-serving is Mir Abid Hussain, appointed in 2011. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Mir Abid Hussain DIN 03372333 | Director | 08 Feb 2011 | 15 yrs 9 mo | Emotion Squared Technologies Private Limited |
| Mohd Baig DIN 03552050 | Director | 03 Jun 2013 | 13 yrs 5 mo | Emotion Squared Technologies Private Limited |
Timeline of HaemO2
2 dated milestones of HaemO2 across 1 years, from founding to its latest funding, stage changes and deals.
- Founded HaemO2 is founded.
- Funding First funding round of $185K.
Competitors of HaemO2
HaemO2 has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of HaemO2
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
3 companies that operate in the same segment as HaemO2 (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about HaemO2
HaemO2 was founded in 2011 and raised its 1st funding round 1 year after it was founded.
HaemO2 is headquartered in United States.
HaemO2 is a funded company, having raised a total of $184.63K across 1 funding round to date. The company's 1st funding round was a Seed of $184.63K, raised on Jan 2012.
HaemO2 operates with a B2B model, focusing on providing healthcare solutions, advancing biotech innovations, developing medical devices, and blood substitutes. Develops engineered hemoglobin for creating advanced blood substitute solutions. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
HaemO2's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
HaemO2 has 1 investor. Key investors include IceniFund.
HaemO2 operates through Emotion Squared Technologies Private Limited.
The legal entities of HaemO2 currently have 2 directors, including Mohd Baig, Mir Abid Hussain.